- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
George Bakris, MD, Lauds FIDELIO-CKD Findings, Discusses Finerenone
Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.
In the phase 3 FIDELIO-DKD trial, finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), slowed the progression of diabetic kidney (DKD) disease in patients with type 2 diabetes by 18% over a median of 2.6 years vs the current standard of care. Finerenone also reduced the composite cardiovascular outcome by 14%.
The results were published online October 23, 2020 in the New England Journal of Medicine.
FIDELIO primary investigator George Bakris, MD, spoke recently with Patient Care about the study and its results in detail. Dr Bakris also describes the properties of finerenone that differentiate the drug from current treatments for DKD and its potential to fill a large unmet clinical need.
Dr Bakris is professor of medicine at the University of Chicago and director of the Comprehensive Hypertension Center at the University of Chicago Medicine. He will present results of an additional FIDELIO analysis at the virtual American Heart Association 2020 Scientific Sessions on Monday, November 16, 2020
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.
